SCHEMBL5876250

SCHEMBL5876250

Cc1ccc(S(=O)(=O)n2nc(C(=O)O)c3c2CC(c2ccccc2)(c2cccnc2)C=C3)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
CYP2C19 P33261 2/20 0.37
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
GBA1 P04062 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
EGFR P00533 1/20 0.34
PTGS2 P35354 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
LMNA P02545 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5877423 0.98 ALDH1A1 (0.36) ALDH1A1CYP2C19NR1H2NR1H3GBA1
SCHEMBL5876231 0.93 CYP2C19 (0.39) ALDH1A1CYP2C19NR1H2NR1H3GBA1
SCHEMBL5876186 0.93 CYP2C19 (0.42) ALDH1A1CYP2C19NR1H2NR1H3LMNA
SCHEMBL5876034 0.90 NR1H2 (0.36) ALDH1A1CYP2C19NR1H2NR1H3PTGS2
SCHEMBL5876013 0.87 ALDH1A1 (0.36) ALDH1A1CYP2C19NR1H2NR1H3GBA1
SCHEMBL5877142 0.87 CYP2C19 (0.38) ALDH1A1CYP2C19NR1H2NR1H3SMN1; SMN2
SCHEMBL5876688 0.86 CYP2C19 (0.36) ALDH1A1CYP2C19NR1H2NR1H3LMNA
SCHEMBL5877004 0.86 ALDH1A1 (0.37) ALDH1A1CYP2C19NR1H2NR1H3SMN1; SMN2
SCHEMBL5876634 0.86 ALDH1A1 (0.42) ALDH1A1CYP2C19NR1H2NR1H3SMN1; SMN2
SCHEMBL5877548 0.86 MAPT (0.42) ALDH1A1CYP2C19NR1H2NR1H3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT ALDH1A1 166/4885CYP2C19 13/4885NR1H2 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.